Menu
In 2020, Vaxinz was born out of the imperative to address the unprecedented challenges posed by the global COVID-19 pandemic. Recognizing the urgency, we forged a unique alliance between public and private entities within the scientific and technological landscape. It was within the crucible of this collaboration that our proprietary technology, centered on Adenoviral Vectors, was conceptualized and subsequently licensed.
Over the past three years, our vision has evolved and matured, drawing strength from the valuable inputs of our esteemed partners and the exponential growth of the Vaxinz team. This collective journey has not only marked the progress of our innovative project but also underlined our unwavering commitment to pioneering solutions in the field of biotechnology. As we reflect on our history, we remain dedicated to the relentless pursuit of excellence, driving advancements that transcend the boundaries of conventional vaccine development.
Vaxinz stands as a dynamic force in biotechnology, evolving beyond its initial focus on SARS-CoV-2 to become a pioneering entity dedicated to generating comprehensive Global health solutions, particularly tailored for the Southern Hemisphere. Our mission encapsulates:
Evolving beyond SARS-CoV-2, Vaxinz is committed to generating holistic health solutions strategically designed for the unique challenges faced by the world, and particularly by the Southern Hemisphere.
CoroVaxG.3.D-FR, our second-generation SARS-CoV-2 vaccine, remains our lead candidate, crafted to provide long-lasting and broad protection against Variants of Concern.
At the heart of our mission is the utilization of advanced biotechnological solutions. Our vaccine platform, marked by a replication-deficient human adenoviral vector, not only propels the development of a single-shot, long-lasting immune protection (ex. against SARS-CoV-2) but also facilitates a swift response to emerging health crises on a global scale.
A core aspect of our mission is to harness our innovative vaccine platform to generate rapid responses to both future pandemics and endemics, contributing to global health resilience.
Our dedication extends beyond our lead candidate, encompassing a robust pipeline that explores new dimensions of vaccine development. This pipeline is intricately designed to address diverse health challenges, including respiratory viruses, mosquito-borne diseases, and future emerging threats.
Vaxinz places a strong emphasis on regional research, development, and production, aiming to meet the urgent healthcare needs of Latin America and Sub-Saharan Africa. This localized approach enhances accessibility, ensuring timely vaccine access for vulnerable populations.
Our mission is rooted in a commitment to bridge healthcare disparities, ensuring that our health solutions, whether for existing challenges or unforeseen health threats, are accessible and equitable globally.
As Vaxinz continues to evolve, our mission reflects a dynamic dedication to redefine biotechnology, foster global collaborations, and contribute to a healthier, more resilient world, where innovative health solutions are readily available to all who need them.